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CASE REPORT Open Access
Rapid and temporary improvement of
depression and anxiety observed following
niraparib administration: a case report
Benjamin E. Jewett1, Merry N. Miller2, Libby A. Ligon1, Zachary Carter1, Ibrahim Mohammad1 and
Gregory A. Ordway1,2*
Abstract
Background: Cancer patients are disproportionately affected by generalized anxiety and major depression. For
many, current treatments for these conditions are ineffective. In this case report, we present a serendipitous case of
anxiety and depression improvement following administration of the poly (ADP-ribose) polymerase (PARP) inhibitor
niraparib.
Case presentation: A 61-year old woman with a 20-year history of mild depression developed recurrent ovarian
carcinoma and was placed on niraparib for maintenance chemotherapy. With the original onset of ovarian cancer,
she experienced an episode of major depression that was resolved with sertraline. After recurrence of ovarian
cancer, she experienced a recurrence of major depression and a new onset of generalized anxiety that failed to
completely respond to multiple medications. After beginning niraparib therapy the patient noticed a rapid
resolution of the symptoms of her anxiety and depression, an effect that was limited to 10–14 days. Due to bone
marrow suppression, the patient was taken off and restarted on niraparib several times. Each discontinuation of
niraparib resulted in return of her depression and anxiety, while each recontinuation of niraparib resulted in an
improvement in her mood and anxiety.
Conclusions: This case demonstrates rapid and temporary improvement of anxiety and depression following niraparib
administration. There is ample preclinical data that PARP signaling may play a role in psychiatric illness. A small amount
of indirect data from clinical trials also shows that niraparib may have psychiatric benefits. Further research on PARP
inhibition and its potential psychoactive effects is sorely needed.
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Background
Patients suffering from cancer are particularly vulnerable
to depression and anxiety, having a rate of major depres-
sive disorder and generalized anxiety disorder several
times higher than that of the general population [1, 2].
Cancer patients with comorbid major depressive
disorder (MDD) have higher mortality rates than those
who do not, and there is evidence that the chronic stress
state associated with MDD may accelerate tumor growth
and invasiveness through a variety of mechanisms [3].
Unfortunately, approximately 30% of patients with
depression and anxiety do not respond or have only a
partial response to antidepressant treatment [4], further
raising risk of poor outcomes in cancer patients.
In this paper, we present a case of rapid temporary
remission of depression and generalized anxiety disorder
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: ordway@etsu.edu
1Department of Biomedical Sciences, PO Box 70577, Johnson City 37614,
USA
2Department of Psychiatry and Behavioral Sciences, East Tennessee State
University, 187 Maple Avenue, Johnson City, TN 37684, USA
Jewett et al. BMC Psychiatry          (2020) 20:171 
https://doi.org/10.1186/s12888-020-02590-4
in an ovarian cancer patient treated with niraparib, a
small molecule inhibitor of poly (ADP-ribose) polymer-
ase (PARP). This case, along with a large number of
studies demonstrating neuroprotective effects of PARP
inhibitors, indicates that further investigation of poten-
tial psychotherapeutic effects of PARP inhibitors is
warranted.
Case presentation
A 61-year old woman presented to her primary care
doctor complaining of chest pain. She had a past med-
ical history of hypothyroidism and 6 years earlier was
diagnosed with stage IIIC papillary carcinoma of the
right ovary, for which she underwent surgery and
chemotherapy. Imaging and laboratory testing confirmed
recurrence of ovarian carcinoma, and she again under-
went surgery and was placed on chemotherapy with
paclitaxel and carboplatin. There was a good therapeutic
response to this therapy; her CA-125 levels normalized,
and she became clinically asymptomatic.
Prior to her cancer, the patient had a long history of
depressive symptoms treated with a variety of antide-
pressants. She reported mild depressive symptoms
associated with recurrent headaches following a hyster-
ectomy at age 35. She had been treated with several anti-
depressants with partial benefit, including nortriptyline,
citalopram, paroxetine, trazodone, and venlafaxine. It is
noted that the patient had a family history of depression
and anxiety in her mother, who did not respond well to
treatment with antidepressants. The patient was first
diagnosed with a major depressive episode after her
initial cancer diagnosis, which was followed by the
deaths of both of her parents. She was treated with
sertraline for several years with benefit, but had further
headaches and discontinued the sertraline for 4 years. At
the time of her cancer recurrence, she experienced an
acute worsening of her depression and the new onset of
severe anxiety. Additional stressors included her
concerns about illnesses that her grandson and best
friend were experiencing. At this time (after cancer
recurrence), she was diagnosed by her psychiatrist with
recurrent MDD and generalized anxiety disorder. She
was treated with escitalopram 20mg/day, augmented
with buspirone 30 mg/day (4 months after starting
escitalopram), as well as lorazepam 0.25 mg as needed
for anxiety. Despite these therapies, she continued to
experience significant depression and anxiety.
Nine months after her cancer recurrence and following
normalization of her CA-125 levels, and 6 months after
starting escitalopram, the patient was started on main-
tenance oral chemotherapy with niraparib 300 mg at
bedtime. The patient reported a dramatic response in
her mood after initiating treatment with niraparib, and
she awoke the next morning feeling no depression or
anxiety. She was very surprised to feel so good, as she
had not experienced a day free of depression and anxiety
since her cancer recurrence. This mood improvement
persisted for approximately 2 weeks.
Unfortunately, the patient developed side effects to
niraparib, including insomnia, thrombocytopenia, and
neutropenia. One month after initiation, niraparib was
held for 2 weeks due to the thrombocytopenia. During
this 2 week period, the patient described a worsening of
her mood, particularly her anxiety. Niraparib was then
restarted at a decreased dose of 200mg/day. The patient
again experienced a dramatic improvement in mood and
anxiety—an effect that lasted for 10 days.
Niraparib was temporarily held again 2 months later
due to neutropenia, and was later restarted at the dose
of 100mg/day. Again the patient described experiencing
a large improvement in her depression and especially in
her anxiety when the niraparib was restarted. Again on
this occasion, the improvement lasted about 10 days.
Eventually, due to thrombocytopenia and neutropenia,
niraparib dosing was lowered to 100 mg every other day.
The patient’s psychiatric medication regimen was ad-
justed during the same time period she was being
treated with niraparib. While on niraparib, the patient
was able to decrease her lorazepam usage down from
0.25–0.50 mg per day to 0.25–0.50 mg once a week.
Several weeks after the niraparib was begun, the patient
was weaned off escitalopram and buspirone due to lack
of efficacy, and she was begun on desvenlafaxine 50mg/
day and mirtazapine 45 mg/day. Five months later, she
was weaned off mirtazapine but stayed on desvenlafaxine
50mg. The patient reported only partial benefit from
these antidepressant medications, in contrast to the
complete, albeit temporary, symptomatic resolution she
initially experienced with niraparib.
For this report, the patient was interviewed by board-
certified psychiatrist coauthor MNM approximately 10
months after her initial treatment with niraparib. MNM
conducted a psychiatric interview and administered
three self-report evaluations (Patient Health Question-
naire, PHQ-9; Generalized Anxiety Disorder-7 item,
GAD7; Mood Disorder Questionnaire, MDQ). At the
time of the interview, the patient’s cancer continued to
be in remission. As a result of the interview and self-
assessments, it was determined that her mood continued
to be mildly dysphoric and anxious but was overall
stable on 50 mg desvenlafaxine daily and 100 mg of nira-
parib every other day. There was no evidence of hypo-
mania or mania in the MDQ, and also no evidence of
bipolar disorder in the patient’s history.
Discussion and conclusions
There are several interesting features of this patient’s
response to niraparib that should be noted. First, the
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onset of the mood improvement following initiation of
niraparib therapy was rapid, taking effect within 12 h.
Likewise, upon discontinuation of niraparib, anxiety and
depression symptoms rapidly returned. Second, it is
important to note that the patient’s symptomatic
response to niraparib appeared time-limited, with symp-
tom resolution lasting only 10–14 days. Third, there did
not appear to be a clinical difference in mood improve-
ment following doses of 300mg versus 100 mg of
niraparib, while the dose decrease did reduce the rate of
side effects.
The mechanism of niraparib’s potential psychoactive
effects is currently unclear. PARP inhibitors are FDA-
approved for the treatment of BRCA-positive breast
cancer and ovarian cancer [5]. PARPs are a family of
enzymes that perform post-translational modification to
proteins to facilitate cellular processes, including DNA
base excision repair. PARPs, particularly PARP1 and
PARP2, are commonly considered DNA base excision
repair enzymes. However, activation of PARP1 is also
directly linked to inflammation cascades, including
activation of NF-κB and production of downstream
cytokines. Besides anti-cancer effects, PARP inhibitors
have anti-inflammatory and neuroprotective properties
and have demonstrated predicted therapeutic activity in
animal models of diseases that involve oxidative stress
and inflammation, including Parkinson’s disease [6],
Alzheimer’s disease [7], ischemic brain injury [8], and
most recently depression [9]. PARP may lie in a pathway
leading to neuroinflammatory cascades in MDD. In fact,
elevated PARP1 gene expression has been reported in
postmortem brain tissue from MDD donors [10] and
from blood cells from patients with MDD [11]. The
rapidity of the effect of niraparib on mood in the present
case might seem to preclude the possibility that effects
on mood were secondary to an anti-inflammatory action.
However, PARP activation modulates the expression of
IL-1β and other cytokines [12] that have been shown to
have direct actions on brain monoamines, including
dopamine, norepinephrine, and serotonin [13–15]. The
temporary nature of the mood benefit possibly elicited
by niraparib in this patient is also noteworthy. Further
research on the mechanisms by which PARP inhibitors
affect mood is sorely needed.
There are two drugs with PARP inhibitory activity that
have antidepressant or mood stabilizing properties,
although a connection between effects on PARP and
mood have not been previously postulated. Minocycline
is a potent PARP inhibitor [16] that also has robust anti-
depressant effects [17]. Laboratory studies have also sug-
gested that lithium may modulate PARP signaling [18].
Recently, two PARP inhibitors, 3-aminobenzaminde and
5-isoquinolinone, have been shown to demonstrate
antidepressant-like activity in preclinical rodent models
(social defeat and chronic unpredictable stress, forced
swim test) with efficacy similar to fluoxetine. Addition-
ally, PARP inhibition appeared to have an additive anti-
depressant effect when combined with fluoxetine [9].
PARP inhibitors have also been shown to protect
rodents from helplessness behavior in inflammation-
induced sickness behavior [19].
We examined data from clinical trials of PARP inhibi-
tors reported at clinicaltrials.gov to determine whether
there was prior evidence of mood improvement in
cancer patients. Only placebo-controlled trials with
group sample sizes of > 20 were considered. It should be
noted that cancer drug trials are not designed to evalu-
ate mood effects and do not use robust psychiatric rating
scales. Several clinical trials of PARP inhibitors report
little or no anxiety and (or depression when measured)
in enrolled cancer patients. Two trials of veliparib that
reported anxiety in some placebo-treated patients
showed a modestly lower incidence of anxiety in PARP
inhibitor-treated patients [20, 21]. In contrast, no such
trend was observed for placebo-controlled trials of
oliparib. No results from clinical trials using niraparib
were posted at the time of writing of this report.
There are many factors that limit the conclusions that
can be drawn from this case report. First, the clinical
course of only one patient is described. This patient was
medically complicated and was treated with multiple
psychoactive drugs during the course of the period
covered by this report. While there is a temporal rela-
tionship between the patient’s symptomatic relief and
initiation of niraparib, there is no way to definitely state
that niraparib resolved the patient’s depression and anx-
iety. Also, each time the niraparib was begun, her
improvement in mood was temporary with the recur-
rence of some of her symptoms after 10 days to 2 weeks.
Brain penetration and retention for many PARP inhibi-
tors is poor and is a deterrent to treating brain cancers
[22]. In contrast, niraparib crosses the blood brain
barrier and accumulates in brain tissue [23]. Finally,
niraparib likely contributed to the development of
thrombocytopenia and neutropenia in this patient.
To our knowledge, this is the first published report of
putative mood effects for a PARP inhibitor in a human
subject. Of course, this is not the first case of a non-
psychiatric drug demonstrating positive psychiatric
effects. Chlorpromazine, the first antipsychotic, was
initially used as a component of general anesthesia, and
its psychoactive effects were first noted by a surgeon
[24]. Likewise, iproniazid, the first monoamine oxidase
inhibitor, was initially developed as an anti-tubercular
agent and its psychoactive effects were only fortuitously
discovered later [25].
While patients often bring negative psychiatric side ef-
fects to the attention of clinicians, positive psychotropic
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effects of drugs may often be overlooked. This case re-
port underlines the need for more research on the rela-
tionship between PARP signaling, depression, and
anxiety at the preclinical, translational, and clinical
levels.
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